Cannabicitran Enantiomer Isolation via Chiral HPLC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current studies on cannabinoids lack information on enantiomeric purity, particularly for cannabicitran (CBT-C), which is crucial for developing effective therapeutics due to the potential differences in biological activities between enantiomers, as seen with other chiral pharmaceuticals like thalidomide and Darvon/Novrad.
Innovation Solution
The method involves isolating and characterizing the enantiomers of cannabicitran using advanced techniques such as ECD, TDDFT calculations, and HPLC, determining the absolute configurations of (−)-CBT-C and (+)-CBT-C, and separating them to create enriched enantiomeric mixtures for enhanced biological activity and safety profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If racemic cannabicitran is used for therapeutic applications, then the available quantity of the compound is sufficient, but the biological activity and safety profile are compromised due to non-equivalent effects of individual enantiomers
Solution Approach 1:
The racemic cannabicitran mixture is segmented into individual enantiomers through chiral separation techniques. The patent applies chromatographic methods on chiral stationary phases to resolve the racemate into pure (R)- and (S)-enantiomers, allowing each to be evaluated and utilized independently for their distinct biological activities and safety profiles.
Solution Approach 2:
Chiral stationary phases serve as intermediaries in the separation process. These specialized phases interact differently with each enantiomer based on their chiral recognition properties, enabling the resolution of the racemic mixture into pure enantiomeric forms that can then be characterized for their respective therapeutic potentials.
2Measurement precision
If enantiomeric separation and characterization methods are implemented, then enantiomeric purity and biological activity information are obtained, but the analytical complexity and measurement difficulty increase
Solution Approach 1:
The patent employs advanced spectroscopic techniques (circular dichroism, vibrational circular dichroism) and computational methods (TDDFT, DFT) to replace traditional mechanical or simple chemical separation methods. These techniques provide direct determination of absolute configuration and enantiomeric purity through optical activity measurements and theoretical calculations, reducing the need for complex multi-step analytical procedures.
Solution Approach 2:
The patent utilizes changes in optical parameters (circular dichroism spectra, vibrational circular dichroism spectra, optical rotation) to characterize enantiomers. By measuring these specific physical parameters that are sensitive to chiral configuration, the method achieves precise enantiomeric identification and purity determination without requiring complex structural analysis.
3Adaptability or versatility
If racemate is used to leverage synergistic effects, then the therapeutic coverage is broader, but the potency and safety are reduced compared to pure enantiomers
Solution Approach 1:
The patent applies the principle of partial action by isolating and evaluating individual enantiomers to determine which one provides the desired therapeutic effect with optimal potency and safety. Rather than using the full racemic mixture, the approach identifies and utilizes only the active enantiomer (or specific enantiomeric ratio) needed for effective therapy, avoiding the dilution of potency that occurs with inactive or harmful enantiomers.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the preparation of enantiomerically enriched cannabicitran, potentially increasing potency and safety by identifying non-equivalent biological activities of individual enantiomers, addressing the racemate's synergistic effects and receptor binding affinities, thus improving the efficacy and safety profiles of cannabinoid-based therapeutics.
Implementation Method 1
isolation and characterization of the enantiomers of cannabicitran using advanced techniques such as ECD, TDDFT calculations, and HPLC
Implementation Method 2
isolation and characterization of the enantiomers of cannabicitran using advanced techniques such as ECD, TDDFT calculations, and HPLC
Data Source
AI summary
In one aspect, compounds and associated pharmaceutical compositions are described herein comprising isolated cannabicitran (CBT-C (3)). In some embodiments, CBT-C (3) enantiomers are isolated and/or prepared. In some further embodiments, the biological activity of enantiomers are determined. In some further embodiments, one or more enantiomers may be incorporated into a composition.